First-in-Class Inhibitors of Oncogenic CHD1L With Preclinical Activity Against Colorectal Cancer

Since the discovery of CHD1L in 2008 it has emerged as an oncogene implicated in the pathology and poor prognosis of a variety of cancers, including gastrointestinal cancers. However, a mechanistic understanding of CHD1L as a driver of colorectal cancer (CRC) has been limited. Until now, there have...

詳細記述

保存先:
書誌詳細
出版年:Mol Cancer Ther
主要な著者: Abbott, Joshua M., Zhou, Qiong, Esquer, Hector, Pike, Laura, Broneske, Travis P., Rinaldetti, Sébastien, Abraham, Adedoyin D., Ramirez, Dominique A., Lunghofer, Paul J., Pitts, Todd M., Regan, Daniel P., Tan, Aik Choon, Gustafson, Daniel L., Messersmith, Wells A., LaBarbera, Daniel V.
フォーマット: Artigo
言語:Inglês
出版事項: 2020
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7665848/
https://ncbi.nlm.nih.gov/pubmed/32499299
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-20-0106
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料